Literature DB >> 10938278

Characterization of a mutation of bacteriophage lambda integrase. Putative role in core binding and strand exchange for a conserved residue.

T Bankhead1, A M Segall.   

Abstract

Site-specific recombination is involved in processes ranging from resolution of bacterial chromosome dimers to adeno-associated viral integration and is a versatile tool for mammalian genetics. The bacteriophage lambda-encoded site-specific recombinase integrase (Int) is one of the best studied site-specific recombinases and mediates recombination via four distinct pathways. We have characterized a mutant version of lambda Int, IntT236I; this mutant can perform the bent-L pathway only, whereas the corresponding IntT236A mutant can perform bent-L, excision and integration pathways. Experiments with both IntT236I and IntT236A show that the hydroxyl group of threonine is necessary for wild-type recombination. Substitution of the threonine by serine leads to nearly complete rescue of the mutant phenotypes. In addition, our data show that the IntT236I mutant is defective partially due to obstructive steric interactions. Comparisons of crystal structures reveal that the threonine at residue 236 may play an important role in stabilizing recombination intermediates through solvent-mediated protein-DNA interactions at the core-binding sites and that the hydroxyl group is important for effective cleavage and Holliday junction formation. Our data also indicate that Int contacts the core sites differently in intermediates assembled in excisive versus bent-L recombination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938278     DOI: 10.1074/jbc.M004679200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  The RAG proteins in V(D)J recombination: more than just a nuclease.

Authors:  M J Sadofsky
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

2.  Regulation of site-specific recombination by the C-terminus of lambda integrase.

Authors:  Robert A Kazmierczak; Brian M Swalla; Alex B Burgin; Richard I Gumport; Jeffrey F Gardner
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

3.  New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.

Authors:  David F Fujimoto; Clemencia Pinilla; Anca M Segall
Journal:  J Mol Biol       Date:  2006-08-24       Impact factor: 5.469

4.  Mutations at residues 282, 286, and 293 of phage lambda integrase exert pathway-specific effects on synapsis and catalysis in recombination.

Authors:  Troy M Bankhead; Bernard J Etzel; Felise Wolven; Sylvain Bordenave; Jeffrey L Boldt; Teresa A Larsen; Anca M Segall
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

5.  The genome of BCJA1c: a bacteriophage active against the alkaliphilic bacterium, Bacillus clarkii.

Authors:  Andrew M Kropinski; Melissa Hayward; M Dorothy Agnew; Ken F Jarrell
Journal:  Extremophiles       Date:  2004-11-17       Impact factor: 2.395

6.  Receipt of the C-terminal tail from a neighboring lambda Int protomer allosterically stimulates Holliday junction resolution.

Authors:  Dane Hazelbaker; Marta Radman-Livaja; Arthur Landy
Journal:  J Mol Biol       Date:  2005-09-02       Impact factor: 5.469

7.  Characterizing Phage Genomes for Therapeutic Applications.

Authors:  Casandra W Philipson; Logan J Voegtly; Matthew R Lueder; Kyle A Long; Gregory K Rice; Kenneth G Frey; Biswajit Biswas; Regina Z Cer; Theron Hamilton; Kimberly A Bishop-Lilly
Journal:  Viruses       Date:  2018-04-10       Impact factor: 5.048

Review 8.  Considerations for the Use of Phage Therapy in Clinical Practice.

Authors:  Gina A Suh; Thomas P Lodise; Pranita D Tamma; Jane M Knisely; Jose Alexander; Saima Aslam; Karen D Barton; Erica Bizzell; Katherine M C Totten; Joseph L Campbell; Benjamin K Chan; Scott A Cunningham; Katherine E Goodman; Kerryl E Greenwood-Quaintance; Anthony D Harris; Shayla Hesse; Anthony Maresso; Veronique Nussenblatt; David Pride; Michael J Rybak; Zoe Sund; David van Duin; Daria Van Tyne; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.